DENVER — Performing catheter ablation of atrial fibrillation without warfarin discontinuation significantly reduced the occurrence of periprocedural stroke and bleeding complications, according to findings from the COMPARE trial.
COMPARE is the first open-label, parallel-group, multicenter study to assess the role of continuous warfarin therapy in the prevention of periprocedural thromboembolic and hemorrhagic events after radiofrequency catheter ablation. Researchers randomly assigned 1,584 patients to discontinue warfarin (n=790) or continue warfarin (n=794).
Full Story »
Personalize your page!
Register for Healio to get content tailored to your specialty and areas of interest.
It’s FREE and only takes one minute.